Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) that affects B-lymphocytes. It develops when B-lymphocytes become abnormal. It is a mature B-cell neoplasm arising from the germinal center and post germinal center B-cells.
Diffuse Large B-Cell Lymphoma Market Insight
Diffuse Large B-Cell Lymphoma market Size in 7MM was USD 2,692 million in 2017.
Diffuse Large B-cell Lymphoma Market Outlook
The Diffuse Large B-cell Lymphoma market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Diffuse Large B-cell Lymphoma market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Diffuse Large B-cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Diffuse Large B-cell Lymphoma market in 7MM is expected to change in the study period 2017-2030.
Diffuse Large B-Cell Lymphoma Market Drivers
- Rising Incidence among Aging population
- Increase in R&D
- CAR-T therapies approvals
Diffuse Large B-Cell Lymphoma Market Barriers
- Availability of defined diagnostic tools
- Delay in Diagnosis
- High cost of treatment
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Diffuse Large B-cell Lymphoma
3. Competitive Intelligence Analysis for Diffuse Large B-cell Lymphoma
4. Diffuse Large B-cell Lymphoma: Market Overview at a Glance
4.1. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2017
4.2. Diffuse Large B-cell Lymphoma Total Market Share (%) Distribution in 2030
5. Diffuse Large B-cell Lymphoma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Diffuse Large B-cell Lymphoma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Diffuse Large B-cell Lymphoma Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Diffuse Large B-cell Lymphoma Treatment and Management
8.2. Diffuse Large B-cell Lymphoma Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Diffuse Large B-cell Lymphoma Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Diffuse Large B-cell Lymphoma: Seven Major Market Analysis
13.1. Key Findings
13.2. Diffuse Large B-cell Lymphoma Market Size in 7MM
13.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Diffuse Large B-cell Lymphoma Total Market Size in the United States
15.1.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Diffuse Large B-cell Lymphoma Total Market Size in Germany
15.3.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Diffuse Large B-cell Lymphoma Total Market Size in France
15.4.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Diffuse Large B-cell Lymphoma Total Market Size in Italy
15.5.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Diffuse Large B-cell Lymphoma Total Market Size in Spain
15.6.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Diffuse Large B-cell Lymphoma Total Market Size in the United Kingdom
15.7.2. Diffuse Large B-cell Lymphoma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Diffuse Large B-cell Lymphoma Total Market Size in Japan
15.8.3. Diffuse Large B-cell Lymphoma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Diffuse Large B-cell Lymphoma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/